Starpharma dendrimer nanotech boosts cancer fight; Hemispherx launches injectable wart treatment in Argentina;

> Australia's Starpharma says a recent clinical study proved the docetaxel chemotherapy drug formulated with its dendrimer nanotechnology was more effective at tumor treatment than docetaxel on its own. Story

> Celator Pharmaceuticals obtained orphan drug status in Europe for CPX-351, its liposomal two-drug combo to treat acute myeloid leukemia. The drug uses liposome injection for drug delivery to maintain the proper ratio of both drugs after injection. Release

> Hemispherx Biopharma has gained regulatory approval to market its Alferon N treatment for genital warts in Argentina. GP Pharm will market the drug, an injectable formulation of natural alpha interferon, under the name Naturaferon. The drug is already approved in the U.S. Release

> SeekingAlpha bets that two biotechs focused on transdermal drug delivery will be generating some post-approval buzz this year: Apricus Biosciences, with its NexACT transdermal drug delivery system for a variety of indications, and BioSante, a biotech focused on oncology and sexual health. Story

> Generex Biotechnology raised $2 million to help fund general operations. The company is developing technology that would allow drugs, in liquid form, to be absorbed by the lining of the inner mouth. Release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.